Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine

Clemente-Tomás, R.; Arciniegas-Perasso, C.A.; Hervás-Hernandis, J.M.; García-Ibor, F.; Río, N. Ruiz-del; Duch-Samper, A.

doi:10.1016/j.oftale.2018.07.006

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The granulomatous anterior uveitis associated with its use was first described by Byles in 2000 [2]. A cumulative total of 39 cases (68 eyes) within 15 reports [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] have been published since then, the greatest number previously reported being 12 cases (19 eyes) in 2015 [4]. To the best of our knowledge, this is the largest case series of brimonidine associated uveitis, including the longest patient follow-up in the literature.…”

Section: Introductionmentioning

confidence: 99%

Brimonidine-associated uveitis – a descriptive case series

et al. 2020

View full text Add to dashboard Cite

Background Anterior uveitis secondary to topical brimonidine administration is rare and not well-defined. In glaucoma patients using brimonidine, one must consider this phenomenon to avoid mis-diagnosis and over-treatment with topical steroids which in turn may increase intraocular pressure (IOP). This is the largest case series including the longest patient follow-up in the current literature. Methods Sixteen patients (26 eyes) with consultant diagnosed brimonidine-associated anterior uveitis in a tertiary referral glaucoma clinic presenting between 2015 and 2019 were included in this retrospective case series. Clinical records were taken for descriptive analysis. Main outcome measures were the key clinical features, and disease course (therapy, IOP control, patient outcome). Results Key features were conjunctival ciliary injection and mutton fat keratic precipitation in all eyes. The findings were bilateral in 10 patients. Time between initiation of brimonidine treatment and presentation was 1 week to 49 months. Glaucoma sub-types were mostly pseudo-exfoliative and primary open angle glaucoma. Brimonidine treatment was stopped immediately. Additionally, topical corticosteroids were prescribed in 18 eyes and tapered down during the following 4 weeks. Thirteen eyes did not need surgical or laser treatment (median follow-up time 15 months). No patient showed recurrence of inflammation after cessation of brimonidine. Conclusions This type of anterior uveitis is an uncommon but important manifestation which should always be considered in glaucoma patients on brimonidine treatment. Although treatable at its root cause, problems may persist, especially with respect to IOP control. The latter may necessitate glaucoma surgery after the resolved episode of the uveitis.

show abstract